Recurrent Ovarian Carcinoma Completed Phase 2 Trials for Sirolimus (DB00877)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerTreatment